Trial Profile
A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sanofi
- 18 Sep 2014 New trial record